CA2737551A1 - Methods and compositions for the treatment of cancer - Google Patents

Methods and compositions for the treatment of cancer Download PDF

Info

Publication number
CA2737551A1
CA2737551A1 CA2737551A CA2737551A CA2737551A1 CA 2737551 A1 CA2737551 A1 CA 2737551A1 CA 2737551 A CA2737551 A CA 2737551A CA 2737551 A CA2737551 A CA 2737551A CA 2737551 A1 CA2737551 A1 CA 2737551A1
Authority
CA
Canada
Prior art keywords
acid ceramidase
cancer
chok
inhibitor
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2737551A
Other languages
English (en)
French (fr)
Inventor
Ana Ramirez De Molina
Lourdes Garcia Oroz
Juan Carlos Lacal Sanjuan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Traslational Cancer Drugs Pharma SL
Original Assignee
Traslational Cancer Drugs Pharma SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Traslational Cancer Drugs Pharma SL filed Critical Traslational Cancer Drugs Pharma SL
Publication of CA2737551A1 publication Critical patent/CA2737551A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/978—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • G01N2333/98—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
CA2737551A 2008-09-17 2009-09-17 Methods and compositions for the treatment of cancer Abandoned CA2737551A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380270 2008-09-17
EP08380270.2 2008-09-17
PCT/EP2009/062078 WO2010031825A2 (en) 2008-09-17 2009-09-17 Methods and compositions for the treatment of cancer

Publications (1)

Publication Number Publication Date
CA2737551A1 true CA2737551A1 (en) 2010-03-25

Family

ID=40364454

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2737551A Abandoned CA2737551A1 (en) 2008-09-17 2009-09-17 Methods and compositions for the treatment of cancer

Country Status (15)

Country Link
US (4) US20100068302A1 (enExample)
EP (1) EP2340042B1 (enExample)
JP (1) JP2012502954A (enExample)
KR (1) KR20110067041A (enExample)
CN (1) CN102215872B (enExample)
AU (1) AU2009294618A1 (enExample)
BR (1) BRPI0919238A2 (enExample)
CA (1) CA2737551A1 (enExample)
DK (1) DK2340042T3 (enExample)
ES (1) ES2527361T3 (enExample)
MX (1) MX2011002956A (enExample)
PL (1) PL2340042T3 (enExample)
PT (1) PT2340042E (enExample)
RU (1) RU2011143520A (enExample)
WO (1) WO2010031825A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
WO2012051415A2 (en) * 2010-10-13 2012-04-19 Mount Sinai School Of Medicine Inhibitors of acid ceramidase and uses thereof in cancer and other disease treatment therapies
EP2468259A1 (en) * 2010-12-23 2012-06-27 Traslational Cancer Drugs Pharma, S.L. Pharmaceutical compositions of pyridinium and quinolinium derivatives
CA2840129A1 (en) 2011-06-20 2012-12-27 Traslational Cancer Drugs Pharma, S.L. Method for predicting the clinical response to chemotherapy in a subject with cancer
SI2753346T1 (sl) 2011-09-07 2020-09-30 Mount Sinai School Of Medicine Ceramidaza in diferenciacija celic
HUE051020T2 (hu) * 2012-06-01 2021-01-28 Icahn School Med Mount Sinai A ceramid szintjei a fertõzések kezelésében és megelõzésében
AU2013280644B2 (en) 2012-06-26 2018-08-02 Jeffrey A. BACHA Methods for treating tyrosine-kinase-inhibitor-resistant malignancies in patients with genetic polymorphisms or AHI1 dysregulations or mutations employing dianhydrogalactitol, diacetyldianhydrogalactitol, dibromodulcitol, or analogs or derivatives thereof
WO2014165216A1 (en) * 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
WO2014160390A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
KR101537030B1 (ko) * 2013-08-23 2015-07-16 (주)바이오디펜스 천적동물의 눈을 포함한 홀로그램을 이용한 농작물 보호방법 및 그 보호기구
WO2015028662A1 (en) 2013-08-30 2015-03-05 Consejo Superior De Investigaciones Cientificas (Csic) Compositions and methods for characterization and amelioration of rheumatoid arthritis
US11299528B2 (en) 2014-03-11 2022-04-12 D&D Pharmatech Inc. Long acting TRAIL receptor agonists for treatment of autoimmune diseases
CA3008392C (en) 2015-12-17 2021-11-09 The Johns Hopkins University Ameliorating systemic sclerosis with death receptor agonists
EP3439687A1 (en) 2016-04-07 2019-02-13 The Johns Hopkins University Compositions and methods for treating pancreatitis and pain with death receptor agonists
CN107362370B (zh) * 2016-05-13 2022-07-26 国家纳米科学中心 一种基于金纳米簇联合NGF siRNA治疗胰腺癌的方法
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
US12458659B2 (en) * 2019-02-06 2025-11-04 The Regents Of The University Of California Methods for treating macrophage-mediated diseases, and methods of identifying agents useful therefore
WO2021035168A1 (en) * 2019-08-22 2021-02-25 Thomas Jefferson University Methods for reprogramming cancer cells
JP7594358B2 (ja) * 2019-11-29 2024-12-04 株式会社ダイセル エクソソーム産生促進剤
CN114644626A (zh) * 2020-12-18 2022-06-21 南京施江医药科技有限公司 一种苯环类化合物及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830916A (en) * 1996-05-23 1998-11-03 Duke University Inhibitor of ceramidase
ES2117950B1 (es) * 1996-08-02 1999-09-16 Univ Granada Nuevos compuestos que bloquean la biosintesis de fosforilcolina y su uso como segundo mensajero en proliferacion celular.
US6511676B1 (en) * 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
GB0121285D0 (en) * 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
ES2237332B1 (es) * 2004-01-14 2006-11-01 Consejo Sup. Investig. Cientificas Derivados de piridinio y quinolinio.
CN1968706A (zh) * 2004-06-03 2007-05-23 霍夫曼-拉罗奇有限公司 用顺铂和egfr－抑制剂治疗
CN102228689A (zh) * 2005-04-13 2011-11-02 科学研究高等机关 鉴定用于癌症治疗的化合物的体外方法
ES2277568B1 (es) * 2005-12-30 2008-04-01 Consejo Superior De Investigaciones Cientificas Derivados de triterpenoquinona y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias.

Also Published As

Publication number Publication date
PT2340042E (pt) 2014-11-27
PL2340042T3 (pl) 2015-01-30
MX2011002956A (es) 2011-08-03
US20120040021A1 (en) 2012-02-16
WO2010031825A2 (en) 2010-03-25
US20150297576A1 (en) 2015-10-22
US20100068302A1 (en) 2010-03-18
EP2340042B1 (en) 2014-07-23
ES2527361T3 (es) 2015-01-22
RU2011143520A (ru) 2013-05-10
JP2012502954A (ja) 2012-02-02
US20110256241A1 (en) 2011-10-20
CN102215872B (zh) 2015-06-10
DK2340042T3 (da) 2014-10-27
AU2009294618A2 (en) 2011-04-14
EP2340042A2 (en) 2011-07-06
WO2010031825A3 (en) 2010-08-19
HK1159498A1 (en) 2012-08-03
AU2009294618A1 (en) 2010-03-25
CN102215872A (zh) 2011-10-12
KR20110067041A (ko) 2011-06-20
BRPI0919238A2 (pt) 2019-09-24

Similar Documents

Publication Publication Date Title
EP2340042B1 (en) Methods and compositions for the treatment of cancer
Zhang et al. CircLIFR synergizes with MSH2 to attenuate chemoresistance via MutSα/ATM-p73 axis in bladder cancer
Gandhirajan et al. Small molecule inhibitors of Wnt/β-catenin/lef-1 signaling induces apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo
Lee et al. The immunohistochemical overexpression of ribonucleotide reductase regulatory subunit M1 (RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer (NSCLC)
Prakash et al. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury
CA2878183A1 (en) Methods of treating fgfr3 related conditions
JP2016516046A (ja) がんの治療方法及びがん薬物耐性を阻止する方法
Boileau et al. Oral treatment with PD‐0200347, an α2δ ligand, reduces the development of experimental osteoarthritis by inhibiting metalloproteinases and inducible nitric oxide synthase gene expression and synthesis in cartilage chondrocytes
WO2010002465A2 (en) Methods for treating neoplasia by inhibiting lactate dehydrogenase and/or nicotinamide phosphoribosyltransferase
US20140199692A1 (en) Translational dysfunction based therapeutics
WO2020033467A1 (en) Methods compositions relating to inhibiting cardiovascular calcification via annexin a1
US20200216906A1 (en) Methods and compositions relating to the diagnosis and treatment of cancer
US20180127748A1 (en) Methods relating to the prevention and treatment of drug resistance
EP2721174A1 (en) Method for predicting the clinical response to chemotherapy in a subject with cancer
JP6975720B2 (ja) 腫瘍の診断および治療におけるＡｋｔ２の使用
EP2082235B1 (en) A method of diagnosis and agents useful for same
US11674184B2 (en) Enhancing radiation sensitivity comprising administering PMVK inhibiting siRNA and shRNA
JP7303407B2 (ja) 腫瘍の診断および治療におけるＡｋｔ２の使用
Kuo et al. Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms
HK1159498B (en) Methods and compositions for the treatment of cancer
CA2633715A1 (en) Translational dysfunction based therapeutics
JP2008230977A (ja) ニチジンを成分とする抗癌剤、および該抗癌剤の感受性増強剤
US20070009509A1 (en) Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
WO2025104221A1 (en) Uses of protein tyrosine phosphatase receptor kappa inhibitors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20140915

FZDE Discontinued

Effective date: 20160919